This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grifka, R. G. Articles by Myers, T. J. Search for Related Content PubMed PubMed Citation Articles by Grifka, R. G. Articles by Myers, T. J. Pubmed/NCBI databases Medline Plus Health Information Congenital Heart Defects

(Circulation. 1995;91:1840-1846.)
© 1995 American Heart Association, Inc.

Articles

New Gianturco-Grifka Vascular Occlusion Device

Initial Studies in a Canine Model

Ronald G. Grifka, MD; Charles E. Mullins, MD; Cesare Gianturco, MD; Michael R. Nihill, MD; Martin P. O'Laughlin, MD; Michael C. Slack, MD; Fred J. Clubb, DVM, PhD; Timothy J. Myers, RRT

From the Lillie Frank Abercrombie Section of Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, and Texas Heart Institute, Houston.

Correspondence to Ronald G. Grifka, MD, Texas Children's Hospital, Pediatric Cardiology, 6621 Fannin St, Houston, TX 77030.

Background Transcatheter closure of cardiovascular defects remains a challenge. Several occlusion devices are available, but each device has limitations. The purpose of this study was to evaluate the new Gianturco-Grifka vascular occlusion device (GGVOD) in a canine model.

Methods and Results A total of 26 GGVODs were implanted as part of short- and long-term studies. In the short-term study, 1 GGVOD was implanted in each of 11 systemic arteries from 3.2 to 9.0 mm in diameter. All 11 arteries were occluded immediately. In the long-term study, an aortopulmonary shunt was placed in 10 dogs (9, Gore-tex graft; 1, subclavian artery) followed by GGVOD implantation; additionally, a GGVOD was implanted in 5 subclavian arteries. The dogs were boarded for 3 to 6 months, then recatheterized and euthanatized. Immediately after implantation, the 5 subclavian arteries and 9 Gore-tex shunts were occluded completely; the 1 subclavian artery shunt had a small residual leak. At recatheterization, all 10 shunts and 5 subclavian arteries were occluded completely. Necropsy revealed all shunts to be occluded, with the aortic and pulmonic orifices covered with a neointimal layer. The mean fluoroscopic time needed for GGVOD implantation was 9 minutes (range, 3 to 22 minutes).

Conclusions (1) In a canine model, the GGVOD is effective for transcatheter occlusion of arteries and aortopulmonary shunts from 3 to 9 mm in diameter. Possible indications in children include aortopulmonary collateral vessels, long patent ductus arteriosus, systemic-pulmonary shunts, AV malformations, and arteries supplying tumors. (2) GGVOD implantation requires a short fluoroscopic time.

Key Words: heart defects, congenital • catheterization • occlusion • ductus arteriosus, patent

This article has been cited by other articles:

				W. C. Kirby, R. D'Sa, and A. Reyes II Possible Steroid-Induced Recurrent Patent Ductus Arteriosus After Device Closure Pediatrics, October 1, 2001; 108(4): 1046 - 1047. [Full Text] [PDF]

				P. S. Rao, S. H. Kim, J.-Y. Choi, C. Rey, J. Haddad, F. Marcon, K. Walsh, and E. B. Sideris Follow-up results of transvenous occlusion of patent ductus arteriosus with the buttoned device J. Am. Coll. Cardiol., March 1, 1999; 33(3): 820 - 826. [Abstract] [Full Text] [PDF]

				H. D. Allen, R. H. Beekman III, A. Garson Jr, Z. M. Hijazi, C. Mullins, M. P. O'Laughlin, and K. A. Taubert Pediatric Therapeutic Cardiac Catheterization : A Statement for Healthcare Professionals From the Council on Cardiovascular Disease in the Young, American Heart Association Circulation, February 17, 1998; 97(6): 609 - 625. [Full Text] [PDF]